Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh,Matthew D. Hellmann,Omid Hamid,Katy K. Tsai,Kimberly Loo,Matthew A. Gubens,Michael Rosenblum,Christina L. Harview,Janis M. Taube,Nathan Handley,Neharika Khurana,Adi Nosrati,Matthew F. Krummel,Andrew Tucker,Eduardo V. Sosa,Phillip J. Sanchez,Nooriel Banayan,Juan C. Osorio,Dan L. Nguyen-Kim,Jeremy Chang,I. Peter Shintaku,Peter D. Boasberg,Emma Taylor,Pamela N. Munster,Alain Algazi,Bartosz Chmielowski,Reinhard Dummer,Tristan Grogan,David Elashoff,Jimmy Hwang,Simone M. Goldinger,Edward B. Garon,Robert H. Pierce,Adil Daud +33 more
Reads0
Chats0
TLDR
Liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases wereassociated with reduced marginal CD8+ T-cell infiltration, providing a potential mechanism for this outcome.Abstract:
We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non-small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival [PFS; objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared with patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation cohort (P = 0.0006). The presence of liver metastasis significantly increased the likelihood of progression (OR, 1.852; P < 0.0001). In a subset of biopsied patients (n = 62), liver metastasis was associated with reduced CD8+ T-cell density at the invasive tumor margin (liver metastasis+ group, n = 547 ± 164.8; liver metastasis- group, n = 1,441 ± 250.7; P < 0.016). A reduced response rate and shortened PFS was also observed in NSCLC patients with liver metastasis [median PFS, 1.8 months; 95% confidence interval (CI), 1.4-2.0], compared with those without liver metastasis (n = 119, median PFS, 4.0 months; 95% CI, 2.1-5.1), P = 0.0094. Thus, liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases were associated with reduced marginal CD8+ T-cell infiltration, providing a potential mechanism for this outcome. Cancer Immunol Res; 5(5); 417-24. ©2017 AACR.read more
Citations
More filters
Journal ArticleDOI
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski,Robert M. Jotte,Federico Cappuzzo,Francisco Orlandi,Daniil Stroyakovskiy,Naoyuki Nogami,Delvys Rodriguez-Abreu,Denis Moro-Sibilot,Christian A. Thomas,Fabrice Barlesi,Gene Grant Finley,Claudia Kelsch,Anthony Lee,Shelley Coleman,Yu Deng,Yijing Shen,Marcin Kowanetz,Ariel Lopez-Chavez,Alan Sandler,Martin Reck +19 more
TL;DR: The addition of atezolizumab to bevacIZumab plus chemotherapy significantly improved progression‐free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD‐L1 expression and EGFR or ALK genetic alteration status.
Journal ArticleDOI
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde,Daniel S. Chen +1 more
TL;DR: Ten key challenges facing cancer immunotherapy are defined, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient.
Journal ArticleDOI
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun,Roger Sun,Elaine Johanna Limkin,Elaine Johanna Limkin,Maria Vakalopoulou,Maria Vakalopoulou,Laurent Dercle,Laurent Dercle,Stéphane Champiat,Shan Rong Han,Loic Verlingue,David Brandao,Andrea Lancia,Andrea Lancia,Andrea Lancia,Samy Ammari,Antoine Hollebecque,Jean-Yves Scoazec,Jean-Yves Scoazec,Aurélien Marabelle,Christophe Massard,Jean-Charles Soria,Jean-Charles Soria,Charlotte Robert,Nikos Paragios,Nikos Paragios,Eric Deutsch,Charles Ferté,Charles Ferté +28 more
TL;DR: A radiomic signature predictive of immunotherapy response by combining contrast-enhanced CT images and RNA-seq genomic data from tumour biopsies to assess CD8 cell tumour infiltration was developed and validated.
Journal ArticleDOI
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck,Tony Mok,Makoto Nishio,Robert M. Jotte,Federico Cappuzzo,Francisco Orlandi,Daniil Stroyakovskiy,Naoyuki Nogami,Delvys Rodriguez-Abreu,Denis Moro-Sibilot,Christian A. Thomas,Fabrice Barlesi,Gene Grant Finley,Anthony Lee,Shelley Coleman,Yu Deng,Marcin Kowanetz,Geetha Shankar,W. Lin,Mark A. Socinski,Tony Sk Mok +20 more
TL;DR: Improved overall survival with ABCP versus BCP was observed in patients with sensitising EGFR mutations, and overall survival in the intention-to-treat population, including EGFR-positive patients and patients with baseline liver metastases.
Journal ArticleDOI
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A. Emens,Leisha A. Emens,Cristina Cruz,Joseph Paul Eder,Fadi Braiteh,Cathie Chung,Sara M. Tolaney,Irene Kuter,Rita Nanda,Philippe A. Cassier,Jean Pierre Delord,Michael S. Gordon,Ehab Elgabry,Ching-Wei Chang,Indrani Sarkar,William Grossman,Carol O'Hear,Marcella Fassò,Luciana Molinero,Peter Schmid +19 more
TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.
References
More filters
Journal ArticleDOI
Hepatitis C Virus Core Protein Subverts the Antiviral Activities of Human Kupffer Cells
Zhengkun Tu,Robert H. Pierce,Jonathan D. Kurtis,Yoshio Kuroki,I. Nicholas Crispe,Mark S. Orloff +5 more
TL;DR: KC are intravascular macrophages that are continuously exposed to, and tolerant of, bacterial TLR ligands, which are delivered via the portal circulation, and HCVc might appear to exploit this unique aspect of immunity in the liver.
Journal ArticleDOI
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
Adil Daud,Antoni Ribas,Caroline Robert,F. Stephen Hodi,Jedd D. Wolchok,Anthony M. Joshua,Wen-Jen Hwu,Jeffrey S. Weber,Tara C. Gangadhar,Richard W. Joseph,Roxana S. Dronca,Amita Patnaik,Hassane M. Zarour,Richard F. Kefford,Jill A. Lindia,Xiaoyun Nicole Li,Scot Ebbinghaus,Soonmo Peter Kang,Omid Hamid +18 more
TL;DR: The anti–PD-1 antibody pembro is approved in the US for treating unresectable or metastatic MEL that progressed following ipilimumab (IPI) and, if BRAF V600 mutant, a BRAF inhibito...
BASIC—LIVER, PANCREAS, AND BILIARY TRACT Hepatitis C Virus Core Protein Subverts the Antiviral Activities of Human Kupffer Cells
Zhengkun Tu,Robert H. Pierce,Jonathan D. Kurtis,Yoshio Kuroki,I. Nicholas Crispe,Mark S. Orloff +5 more
TL;DR: In this paper, the effects of hepatitis C virus core protein (HCVc) on human primary kupffer cells (KC) were examined for production of cytokines, expression of programmed death-ligand 1 (PD-L1), secretion of type 1 interferons (IFNs), and expression of the apoptosis-inducing protein tumor necrosis factor (TNF)related apoptosisinducing ligand (TRAIL).
Journal ArticleDOI
Immunological tolerance. The liver effect
TL;DR: The developing immune system in the embryo is programmed to accept all its own tissues as self‐products and not react against them, so that an allografted liver can sometimes survive permanently without any immunosuppressive treatment in immunologically mature animals.
Journal ArticleDOI
Immunological tolerance: the liver effect.
TL;DR: In pigs and rats, an allografted liver can sometimes survive permanently without any immunosuppressive treatment in immunologically mature animals.
Related Papers (5)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more